Overview

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Tesaro, Inc.

Treatments:

8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one
Rolapitant